Is Electromotive Mitomycin C an Alternative Treatment for Frail Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Failed Intravesical BCG?

Frail Patients ◽

Intravesical Bcg ◽

Upper urinary tract surveillance in patients with high risk non-muscle invasive bladder cancer managed with intravesical BCG

European Urology Open Science ◽

10.1016/s2666-1683(20)36267-4 ◽

2020 ◽

Vol 21 ◽

pp. S234

Author(s):

H. Baig ◽

G.M. Nandwani

Keyword(s):

Bladder Cancer ◽

Urinary Tract ◽

High Risk ◽

Upper Urinary Tract ◽

Invasive Bladder Cancer ◽

Intravesical Bcg ◽

Cystectomy outcomes in patients who have failed Radiofrequency-induced Thermo-chemotherapeutic Effect Mitomycin-C (RITE-MMC) treatment for high-risk non-muscle invasive bladder cancer (HRNMIBC)–Does it complicate surgery and adversely impact oncological outcome?

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2020.09.016 ◽

2020 ◽

Author(s):

Denosshan Sri ◽

Hack Jae Lee ◽

Sarah El-Gemmal ◽

Chris Backhouse ◽

Andrea Tay ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Oncological Outcome ◽

Invasive Bladder Cancer ◽

Chemotherapeutic Effect ◽

PD19-07 ONE-YEAR FOLLOW-UP RESULTS AFTER SEQUENTIAL INTRAVESICAL BACILLUS CALMETTE-GUÉRIN AND DEVICE-ASSISTED CHEMO-HYPERTHERMIA (MITOMYCIN C DELIVERED BY THE COMBAT BRS SYSTEM) FOR HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS...A BACILLUS CALMETTE-GUÉRIN-SPARING STRATEGY

The Journal of Urology ◽

10.1016/j.juro.2017.02.880 ◽

2017 ◽

Vol 197 (4S) ◽

Cited By ~ 1

Author(s):

TR Leyshon Griffiths ◽

William JF Green ◽

Peter T Grice ◽

Jonathan C Goddard ◽

Roger C Kockelbergh

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Patients ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Muscle Invasive ◽

One Year

MP56-15 SEQUENTIAL BCG / ELECTROMOTIVE DRUG ADMINISTRATION (EMDA) MITOMYCIN C (MMC) AS THE STANDARD INTRAVESICAL REGIMEN IN HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER (NMIBC) – ONE YEAR OUTCOMES

The Journal of Urology ◽

10.1016/j.juro.2014.02.1583 ◽

2014 ◽

Vol 191 (4S) ◽

Author(s):

Christine Gan ◽

Suzanne Amery ◽

Kathryn Chatterton ◽

Muhammad Shamim Khan ◽

Kay Thomas ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

One Year ◽

Electromotive Drug Administration

1658 EFFICACY OF IMMEDIATE POST-TUR MITOMYCIN-C (MMC) INSTILLATION IN HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GUERIN (BCG)

The Journal of Urology ◽

10.1016/j.juro.2011.02.1768 ◽

2011 ◽

Vol 185 (4S) ◽

Author(s):

Moon-Ki Jo ◽

Kanghyon Song ◽

Jong-Wook Park

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Mitomycin C ◽

Invasive Bladder Cancer ◽

Bacillus Calmette Guerin ◽

Intravesical sequential BCG/electromotive drug administration Mitomycin C (EMDA-MMC) in high risk non muscle invasive bladder cancer – results from a retrospective analysis

European Urology Supplements ◽

10.1016/s1569-9056(18)33383-9 ◽

2018 ◽

Vol 17 (8) ◽

pp. 357-358

Author(s):

F. Di Modugno ◽

V. Pagliarulo ◽

A. Procacci ◽

F. Bianchi ◽

S. Tafuri ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Retrospective Analysis ◽

Mitomycin C ◽

Drug Administration ◽

Invasive Bladder Cancer ◽

Muscle Invasive ◽

Electromotive Drug Administration

Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non-muscle invasive bladder cancer?

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e15544 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e15544-e15544

Author(s):

Savino Mauro Di Stasi ◽

Claus Riedl ◽

Cristian Verri ◽

Francesco Celestino ◽

Francesco De Carlo ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Intravesical Therapy ◽

Intravesical Bcg ◽

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage

Current Urology Reports ◽

10.1007/s11934-016-0625-z ◽

2016 ◽

Vol 17 (9) ◽

Cited By ~ 27

Author(s):

Rajan Veeratterapillay ◽

Rakesh Heer ◽

Mark I. Johnson ◽

Raj Persad ◽

Christian Bach

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Cancer Therapy ◽

Invasive Bladder Cancer ◽

Therapy Options ◽

Intravesical Bcg ◽

HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial

European Urology Supplements ◽

10.1016/s1569-9056(19)30563-9 ◽

2019 ◽

Vol 18 (1) ◽

pp. e768-e770 ◽

Cited By ~ 1

Author(s):

D.A. González Padilla ◽

A. González Díaz ◽

N. Miranda-Utrera ◽

F. De La Rosa Kehrmann ◽

F. Villacampa-Aubá ◽

...

Keyword(s):

Bladder Cancer ◽

Randomized Controlled Trial ◽

High Risk ◽

Mitomycin C ◽

Controlled Trial ◽

Invasive Bladder Cancer ◽

Preliminary Results ◽

Randomized Controlled ◽

COVID‐19 infection threat in patients with high‐risk non‐muscle invasive bladder cancer receiving intravesical BCG therapy

International Journal of Clinical Practice ◽

10.1111/ijcp.13752 ◽

2020 ◽

Author(s):

Serkan Akan ◽

Caner Ediz ◽

Yunus Emre Kızılkan ◽

Adem Alcin ◽

Hasan Huseyin Tavukcu ◽

...

Keyword(s):

Bladder Cancer ◽

High Risk ◽

Invasive Bladder Cancer ◽

Bcg Therapy ◽

Intravesical Bcg ◽

Muscle Invasive ◽

Intravesical Bcg Therapy